BiotechTube

MK-3415 + MK-6072 + MK-3415A + Placebo + SOC

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Clostridium Difficile Infection

Conditions

Clostridium Difficile Infection

Trial Timeline

Oct 10, 2011 → Dec 9, 2014

NCT ID
NCT01241552

About MK-3415 + MK-6072 + MK-3415A + Placebo + SOC

MK-3415 + MK-6072 + MK-3415A + Placebo + SOC is a phase 3 stage product being developed by Merck for Clostridium Difficile Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT01241552. Target conditions include Clostridium Difficile Infection.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01241552Phase 3Completed

Competing Products

20 competing products in Clostridium Difficile Infection

See all competitors
ProductCompanyStageHype Score
Fidaxomicin + Vancomycin + PlaceboAstellas PharmaApproved
85
Fidaxomicin + Treatment for CDI other than fidaxomicin TypeAstellas PharmaPre-clinical
23
OPT-80 + vancomycinAstellas PharmaPhase 3
77
Fidaxomicin oral suspension + Fidaxomicin tablets + Vancomycin oral liquid + Vancomycin capsulesAstellas PharmaPhase 3
77
Fidaxomicin + VancomycinAstellas PharmaApproved
85
Fidaxomicin + VancomycinMerckApproved
85
fidaxomicin + PlaceboMerckPhase 3
77
Surotomycin + PlaceboMerckPhase 1
33
CB-183,315 + Placebo + VancomycinMerckPhase 2
52
Surotomycin + PlaceboMerckPhase 1
33
MK-6072 + MK-3415A + Placebo + SOCMerckPhase 3
77
Vancomycin + FidaxomicinMerckApproved
85
FidaxomicinMerckPre-clinical
23
Bezlotoxumab + Standard CDI treatmentMerckPre-clinical
23
Fidaxomicin + Vancomycin + Matching Placebo to FidaxomicinMerckPhase 3
77
bezlotoxumab + Vancomycin OralMerckApproved
85
Bezlotoxumab + Placebo + Antibacterial drug treatment (ABD)MerckPhase 3
77
Bezlotoxumab Injection [Zinplava]MerckPre-clinical
23
PAR-101/OPT-80 + VancomycinMerckPhase 3
77
fidaxomicinMerckPhase 2
52

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85